AYTU
Aytu BioPharma·NASDAQ
--
--(--)
--
--(--)
AYTU fundamentals
Aytu BioPharma (AYTU) Revenue Breakdown: Q2 2026 Business & Regional Performance
Aytu BioPharma (AYTU) reported total revenue of 15.16M USD in Q2 2026, with its core business segment EXXUA contributing 1.59%. Regionally, United States remained the largest market, accounting for 99.35% of total revenue. Explore Aytu BioPharma's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
Aytu BioPharma (AYTU) reported total revenue of 15.16M USD in Q2 2026, with its core business segment EXXUA contributing 1.59%. Regionally, United States remained the largest market, accounting for 99.35% of total revenue. Explore Aytu BioPharma's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What is Aytu BioPharma's gross profit margin?What factors drove the changes in Aytu BioPharma's revenue and profit?What were the key takeaways from Aytu BioPharma’s earnings call?What guidance did Aytu BioPharma's management provide for the next earnings period?What were the key takeaways from Aytu BioPharma's earnings call?What does Aytu BioPharma do and what are its main business segments?What is the revenue and EPS growth rate for Aytu BioPharma year over year?What is Aytu BioPharma's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
